ANALYSIS: Australian device approvals could slide further with scrutiny hurdles
This article was originally published in SRA
The number of new medtech products on the Australian market has slowly declined over the six months to March 2013 and looks set to fall further if, as expected, tougher approval requirements are introduced for higher risk products.
You may also be interested in...
The deal combines two of the largest providers of sterilization and infection-prevention products to create a $4bn-plus-revenue business.
One of the few silver linings in a tumultuous year dominated by a global pandemic was the huge boost given to the diagnostics and telehealth sectors. But while new technologies for rapid testing for COVID-19 and remote monitoring tools dominated the headlines, there were also key developments in robotic surgery, early-stage cancer testing and cardiac arrhythmia treatment. Here are Medtech Insight’s most popular R&D stories in 2020.
After years of setbacks, the company will launch its device in Europe as a bridge to transplant in heart failure patents.